SDS

_____________________________________________________________________________________________
1195752 - JS17650
Revision Date 02-Feb-2015
Information on toxicological effects
Symptoms
Erythema (skin redness). May cause redness and tearing of the eyes.
Delayed and immediate effects as well as chronic effects from short and long-term exposure
Sensitization
No information available.
Mutagenic Effects
No information available.
Carcinogenicity
The table below indicates whether each agency has listed any ingredient as a carcinogen.
Chemical name ACGIH IARC NTP OSHA
Lithium Cobalt Oxide
(CoLiO2)
12190-79-3
A3 Group 2B X
ACGIH (American Conference of Governmental Industrial Hygienists)
A3 - Animal Carcinogen
IARC (International Agency for Research on Cancer)
Group 2B - Possibly Carcinogenic to Humans
OSHA (Occupational Safety and Health Administration of the US Department of Labor)
X - Present
Reproductive toxicity
Contains a known or suspected reproductive toxin.
STOT - single exposure
No information available.
STOT - repeated exposure
Causes damage to organs through prolonged or repeated exposure. Based on
classification criteria from the 2012 OSHA Hazard Communication Standard (29 CFR
1910.1200), this product has been determined to cause systemic target organ toxicity from
chronic or repeated exposure. (STOT RE).
Chronic Toxicity
Contains a known or suspected carcinogen. Contains a known or suspected reproductive
toxin. Possible risk of irreversible effects. Avoid repeated exposure. Prolonged exposure
may cause chronic effects. May cause adverse liver effects.
Target Organ Effects
Respiratory system. Eyes. Skin. Reproductive System. Central Vascular System (CVS).
Kidney. Liver. Bone marrow. Endocrine system. Lungs. Spleen.
Aspiration Hazard
No information available.
Numerical measures of toxicity Product Information
The following values are calculated based on chapter 3.1 of the GHS document
ATEmix (oral)
23,232.00 mg/kg
ATEmix (dermal)
16,077.00 mg/kg (ATE)
ATEmix (inhalation-dust/mist)
142.00 mg/l
_____________________________________________________________________________________________
Page 8 / 13